<DOC>
	<DOCNO>NCT00838253</DOCNO>
	<brief_summary>The purpose study assess safety efficacy istaroxime patient hospitalize Acute Decompensated Heart Failure ( ADHF ) require inotropic therapy.This do compare hemodynamic effect 24-hour infusion three different dos drug versus placebo . Efficacy measure change Pulmonary Capillary Wedge Pressure pre-infusion 6 hour infusion start . Secondary objective include evaluation clinical efficacy safety assessment cardiovascular renal tolerability well change biological marker brain natriuretic peptide ( BNP ) troponin I ( TNI ) , neurohormones renin aldosterone also assess pharmacokinetics istaroxime metabolite .</brief_summary>
	<brief_title>Safety Efficacy Study Istaroxime Acute Decompensated Heart Failure Patients</brief_title>
	<detailed_description>The 32-day study include 48-hour screening period , 30-minute 2-hour pre treatment period , maximum 2-hour period randomization measurement baseline value , 24-hour treatment period , 96-hour post-treatment period . A 25-day follow-up period include visit Day 30 take place active phase study When consider eligible , first cohort 88 patient randomize 3:1 ratio receive 24-hrs treatment istaroxime 0.5 μg/kg/min placebo . If continuous safety monitoring interim analysis DMC determines safety issue dose , second cohort 88 patient randomize 3:1 ratio receive 24-hrs treatment istaroxime 1.0 μg/kg/min placebo . If continuous safety monitoring interim analyse second cohort DMC determine safety issue dose , third cohort 88 patient randomize 3:1 ratio receive 24-hrs treatment istaroxime 1.5 μg/kg/min placebo . In cohort , patient receive standard care therapy .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<criteria>Male female patient ≥18 year ; Admission ADHF Systolic blood pressure ≤ 120 mmHg ; Ejection fraction ( EF ) ≤ 35 % Signed informed consent . Randomization inclusion criterion : Persistence ADHF sign despite initial treatment i.v . diuretic and/or vasodilator ; Cardiac index ≤ 2.5 L/min/m² ; Pulmonary capillary wedge pressure ≥ 20 mmHg Systolic BP 85 120 mmHg ( limit include ) without sign symptom hypoperfusion Main screening exclusion criterion : Positive pregnancy test female childbearing potential ; Systolic blood pressure &lt; 85 mmHg &gt; 120 mmHg ; Oral treatment digoxin within one week current hospitalization ; Any inotrope administer current hospitalization Presence cardiogenic shock occurrence within past month ; Acute coronary syndrome within past 3 month ; Coronary artery bypass graft percutaneous coronary intervention within past month ; Stroke within past 6 month ; Atrial fibrillation uncontrolled HR ( HR &gt; 100 beat per minute ( bpm ) ; Life threaten ventricular arrhythmia ICD ( implantable cardioverter defibrillator ) shock within past month ; Presence CRT ( cardiac resynchronization therapy ) , ICD pacemaker device implant within past month ; Second third degree atrioventricular block without pacemaker ; Abnormal safety lab value obtain within last 24 hour screen period prior pulmonary arterial catheter ( PAC ) insertion Randomization exclusion criterion : Any inotrope administer current hospitalization period Heart rate &gt; 120 bpm &lt; 50 bpm ; cTnI &gt; 0.5 ng/mL cTnI &gt; ULN &gt; 1.25x first screen assessment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
	<keyword>Acute Heart Failure</keyword>
	<keyword>Inotropes</keyword>
	<keyword>Lusitropic agent</keyword>
	<keyword>Istaroxime</keyword>
	<keyword>Debio 0614</keyword>
</DOC>